# QUAZAR AML-001 (NCT01757535)

> Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01757535
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Celgene
- Conditions: Leukemia, Myeloid, Acute
- Interventions: Oral Azacitidine; Placebo
- Enrollment: 472
- Primary outcome: Kaplan-Meier (K-M) Estimate for Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 6
- Podcasts: 4
- YouTube: 1
- Bluesky threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=quazar-aml-001-nct01757535

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01757535", "email": "<work email>"}; the inbox owner confirms by the emailed link.